XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue
 3 Months Ended
Apr. 04, 2021
Revenue from Contract with Customer [Abstract]  
Revenue
2. REVENUE
Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, and development and licensing agreements.

Revenue by Source

Q1 2021Q1 2020
In millionsSequencingMicroarrayTotalSequencingMicroarrayTotal
Consumables$695 $79 $774 $553 $67 $620 
Instruments176 3 179 79 2 81 
Total product revenue871 82 953 632 69 701 
Service and other revenue108 32 140 128 30 158 
Total revenue$979 $114 $1,093 $760 $99 $859 

Revenue by Geographic Area

Based on region of destination (in millions)Q1 2021Q1 2020
Americas$562 $477 
Europe, Middle East, and Africa305 221 
Greater China (1)127 84 
Asia-Pacific99 77 
Total revenue$1,093 $859 
(1) Region includes revenue from China, Taiwan, and Hong Kong.
Performance Obligations

We regularly enter into contracts with multiple performance obligations. Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of April 4, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $1,129 million, of which approximately 91% is expected to be converted to revenue in the next twelve months, approximately 8% in the following twelve months, and the remainder thereafter.

Contract Liabilities
Contract liabilities, which consist of deferred revenue and customer deposits, as of April 4, 2021 and January 3, 2021 were $232 million and $230 million, respectively, of which the short-term portions of $188 million and $186 million, respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded in Q1 2021 included $83 million of previously deferred revenue that was included in contract liabilities as of January 3, 2021.